Mark P. Colonnese
Director of Finance/CFO chez Covanos, Inc.
Profil
Mark P.
Colonnese currently works at Covanos, Inc., as Chief Financial Officer from 2018.
Mr. Colonnese also formerly worked at Endeavor Pharmaceuticals, Inc., as Director from 1994 to 1997, Bio-Path Holdings, Inc., as Independent Director from 2017 to 2019, Schering-Plough Corp., as Vice President-Financial Operations, AAIPharma, Inc., as Chief Financial Officer & Vice President-Finance from 1993 to 1997, AtheroGenics, Inc., as CFO & EVP-Commercial Operations from 1999 to 2009, Transgenomic, Inc., as CFO, Secretary, EVP & Head-Investor Relations in 2014, Medaphis Corp., as Chief Financial Officer & Senior Vice President from 1997 to 1998, Salutria Pharmaceuticals, Inc., as Chief Financial Officer from 1999 to 2012, Aviragen Therapeutics, Inc., as Chief Financial Officer & Executive Vice President from 2015 to 2018, Vaxart, Inc., as Chief Financial Officer & Executive Vice President, and Stealth BioTherapeutics Corp., as Chief Financial Officer from 2014 to 2015.
Mr. Colonnese received his Masters Business Admin degree from Fairleigh Dickinson University and undergraduate degree from Ithaca College.
Postes actifs de Mark P. Colonnese
| Sociétés | Poste | Début |
|---|---|---|
Covanos, Inc.
 Covanos, Inc. Packaged SoftwareTechnology Services Covanos, Inc. is an American medical technology company that has developed a technology platform combining advanced mathematical methods and computational fluid dynamics with clinical imaging to determine the functional significance of arterial blockages. The private company is based in Atlanta and was founded by Habib Samady. The company's first product, C-Heart, is a non-invasive, out-patient based, point-of-care, PC-based workstation solution that determines whether a patient with chest pain requires re-vascularization of a coronary artery blockage. Russell M. Medford has been the CEO of the company since 2014. | Director of Finance/CFO | 01/09/2018 |
Anciens postes connus de Mark P. Colonnese
| Sociétés | Poste | Fin |
|---|---|---|
| BIO-PATH HOLDINGS, INC. | Director/Board Member | 10/10/2019 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director of Finance/CFO | 01/02/2018 |
| STEALTH BIOTHERAPEUTICS CORP | Director of Finance/CFO | 01/01/2015 |
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Director of Finance/CFO | 30/10/2014 |
Salutria Pharmaceuticals, Inc.
 Salutria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Salutria Pharmaceuticals, Inc. operates drug stores. | Director of Finance/CFO | 01/01/2012 |
Formation de Mark P. Colonnese
| Fairleigh Dickinson University | Masters Business Admin |
| Ithaca College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIO-PATH HOLDINGS, INC. | Health Technology |
| VAXART, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
AAIPharma, Inc.
 AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Commercial Services |
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
Endeavor Pharmaceuticals, Inc.
 Endeavor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endeavor Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on women's health by developing and marketing advanced hormone therapies. The company is headquartered in Wilmington, NC. | Health Technology |
| Medaphis Corp. | Technology Services |
Salutria Pharmaceuticals, Inc.
Salutria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Salutria Pharmaceuticals, Inc. operates drug stores. | Retail Trade |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
Covanos, Inc.
Covanos, Inc. Packaged SoftwareTechnology Services Covanos, Inc. is an American medical technology company that has developed a technology platform combining advanced mathematical methods and computational fluid dynamics with clinical imaging to determine the functional significance of arterial blockages. The private company is based in Atlanta and was founded by Habib Samady. The company's first product, C-Heart, is a non-invasive, out-patient based, point-of-care, PC-based workstation solution that determines whether a patient with chest pain requires re-vascularization of a coronary artery blockage. Russell M. Medford has been the CEO of the company since 2014. | Technology Services |
